Tyme Technologies Inc
North American company
News & analysis
Times are shown in GMT-4, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans. SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. The company is currently conducting a Phase II trial in prostate cancer.Tyme Technologies Inc is a clinical-stage pharmaceutical company focused on discovering and developing targeted cancer therapeutics for a broad range of oncology indications. The company is developing proprietary combination drug product.
Latest TYME News